Freek J. Beekman

Prof. Freek J. Beekman is a Full Professor and head of the Biomedical Imaging section within the Department of Radiation Science & Technology at Delft University of Technology (TU Delft), Faculty of Applied Sciences. He is a leading figure in biomedical imaging, with extensive contributions to nuclear imaging technologies, including SPECT, PET, and CT. His research spans detector development, image reconstruction algorithms, hybrid photonic imaging, and the application of artificial intelligence in medical imaging.

Research Interests: His work focuses on advancing imaging modalities through innovations in hardware (e.g., multi-pinhole collimators) and software (e.g., deep learning for attenuation correction). He has pioneered ultra-high-resolution imaging systems, particularly for preclinical and clinical SPECT, and has developed integrated platforms like U-SPECT-BioFluo. His recent research explores glymphatic delivery of nanoparticles, infection imaging, and AI-driven reconstruction techniques, reflecting a strong translational focus.

Publication Trends: His most recent publications (2021–2023) emphasize deep learning in SPECT, multi-isotope imaging, high-resolution ex vivo systems, and applications in neuroimaging and oncology. The articles demonstrate a consistent focus on improving image quality, resolution, and clinical utility through physics-informed and AI-enhanced methods.

• Scientific Awards:
• NWO Physics Valorization Prize
• Innovation of the Year Award by the World Molecular Imaging Society (2015, 2018)
• Edward Hoffman Memorial Award (2017)
• Bruce Hasegawa Memorial Award (2021)
• FOM Valorization Award (2013)
• TU Delft Entrepreneurial Award (2010)

Advising and Grants: While specific student names are not listed, his leadership in large collaborative projects and supervision of numerous publications suggests active mentoring. He has secured significant funding through national and international grants, evidenced by his invention of over 20 patent families and successful technology transfer. His founding and leadership of MILabs BV (sold to Rigaku) highlights his impact on commercialization and industry-academia collaboration.

Labs and Teams: He leads the Biomedical Imaging research group at TU Delft, which develops cutting-edge imaging systems such as VECTor (SPECT-PET) and EXIRAD-HE. His teams have produced technologies used globally in academic and pharmaceutical research, contributing to tracer development and therapeutic innovation.